Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

A positive from ICER report- Lupkynis is less expensive than Benlysta

6. Now that voclosporin has been approved by the FDA, its
actual list price and reported net revenue per patient
have been reported. The estimated revenue of $65,000
per year to the company (which we assume is equivalent
to the net price since it is much lower than the reported
list price of $144,175 based on $3,950 for a ten-day
supply at full dosage), represents a cost per QALY that –
according to our analysis of the information ICER
included in the draft report – is approximately 25% less
than the cost per QALY for belimumab.
Given that the definition of value is benefits (which could
include clinical, patient, health system, and society
benefits) divided by cost, the company’s reported pricing
for voclosporin seems to be completely appropriate, and
since it is orally administered, an even higher net price
could be justified. That is, the company’s pricing for
voclosporin reflects the clinical and other benefits it
provides.

Above found on pages 22-23:

https://icer.org/wp-content/uploads/2020/11/ICER_Lupus-Nephritis_Public-Comment-Grid_031221.pdf

QUALY = quality-adjusted life-year
The quality-adjusted life-year (QALY) is a measure of the value of health outcomes. Since health is a function of length of life and quality of life, the QALY was developed as an attempt to combine the value of these attributes into a single index number.